Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NGcGM3 ganglioside: a privileged target for cancer vaccines.
Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, Gomez DE, Alonso DF. Fernandez LE, et al. Among authors: gomez de, gomez re. Clin Dev Immunol. 2010;2010:814397. doi: 10.1155/2010/814397. Epub 2010 Oct 27. Clin Dev Immunol. 2010. PMID: 21048926 Free PMC article. Review.
1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients.
Alfonso S, Diaz RM, de la Torre A, Santiesteban E, Aguirre F, Pérez K, Rodríguez JL, Barroso Mdel C, Hernández AM, Toledo D, Gabri MR, Alonso DF, Viada C, Gómez RE, Suárez E, Vazquez AM, Perez R, Macias AE. Alfonso S, et al. Among authors: gomez re. Cancer Biol Ther. 2007 Dec;6(12):1847-52. doi: 10.4161/cbt.6.12.5000. Epub 2007 Sep 8. Cancer Biol Ther. 2007. PMID: 18075301 Clinical Trial.
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Mol Cell Biochem. 2008 Sep;316(1-2):163-7. doi: 10.1007/s11010-008-9814-5. Epub 2008 Jun 25. Mol Cell Biochem. 2008. PMID: 18575815 Clinical Trial.
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7. Mol Cell Biochem. 2011. PMID: 21735096 Clinical Trial.
A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.
Weinberg RS, Grecco MO, Ferro GS, Seigelshifer DJ, Perroni NV, Terrier FJ, Sánchez-Luceros A, Maronna E, Sánchez-Marull R, Frahm I, Guthmann MD, Di Leo D, Spitzer E, Ciccia GN, Garona J, Pifano M, Torbidoni AV, Gomez DE, Ripoll GV, Gomez RE, Demarco IA, Alonso DF. Weinberg RS, et al. Among authors: gomez re. Springerplus. 2015 Aug 19;4:428. doi: 10.1186/s40064-015-1217-y. eCollection 2015. Springerplus. 2015. PMID: 26306290 Free PMC article.
38 results